Allen & Overy advises cancer immunotherapies pioneer iOmx Therapeutics on 65 million Euro Series B financing round
Related people
Headlines in this article
Related news and insights
News: 21 March 2024
Allen & Overy advises arrangers on takeover of Encavis by KKR
News: 20 February 2024
Allen & Overy advises Uniper on sale of Hungarian gas fired power plant Gönyű to Veolia
News: 20 February 2024
News: 09 February 2024
Allen & Overy advises Sartorius group on EUR1.4bn equity raising
The new funds will be invested to advance the company’s lead program IMT-07, a SIK3 kinase inhibitor to treat solid tumors, through the first-in-man clinical trial, and to further develop IMT-18, a first-in-class IGSF11-targeting antibody to treat PD-1/PD-L1-resistant tumors. In addition, iOmx will continue to leverage its target discovery platform, iOTarg, to advance additional novel immune checkpoint programs to lead candidate stage.
iOmx Therapeutics, located in Martinsried/Munich, Germany, is focused on developing first-in-class cancer immunotherapies addressing novel immune checkpoints hijacked by cancer cells. Utilizing its iOTarg™ high-throughput screening platform, iOmx has identified a number of proprietary tumor-associated next-generation immune checkpoints and is advancing a preclinical stage pipeline of promising drug candidates that have the potential to address cancers that are resistant to current immunotherapies.
The Allen & Overy team was led by partner Dr Alexander Veith and comprised counsel Dr Jens Wagner (both Munich) and Dr Andre Wandt (Frankfurt) as well as associates Michael Haase and Linda Mayer (all Corporate/M&A, both Munich).